Insider · CIK 0001603163
Albert D. Bolles
director
Files at STKL (SunOpta Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | STKL SunOpta Inc. | AGrant or award Common Shares | +1,662 | $6.39 | $11k | 231,646 | Feb 12, 2026 |
| Oct 17, 2025 | STKL SunOpta Inc. | AGrant or award Common Shares | +1,806 | $5.68 | $10k | 229,984 | Oct 21, 2025 |
| Jul 25, 2025 | STKL SunOpta Inc. | AGrant or award Common Shares | +1,810 | $6.64 | $12k | 228,178 | Jul 28, 2025 |
| Jul 25, 2025 | STKL SunOpta Inc. | AGrant or award Restricted Stock Unitsderivative | +2,423 | $0.00 | $0 | 20,193 | Jul 28, 2025 |
| May 29, 2025 | STKL SunOpta Inc. | MOption exercise Common Shares | +20,072 | - | - | 226,368 | May 30, 2025 |
| May 29, 2025 | STKL SunOpta Inc. | AGrant or award Restricted Stock Unitsderivative | +17,770 | $0.00 | $0 | 17,770 | May 30, 2025 |
| May 29, 2025 | STKL SunOpta Inc. | MOption exercise Restricted Stock Unitsderivative | -20,072 | $0.00 | $0 | 0 | May 30, 2025 |
| Apr 17, 2025 | STKL SunOpta Inc. | AGrant or award Common Shares | +2,186 | $3.90 | $8,525 | 206,296 | Apr 21, 2025 |
| Jan 24, 2025 | STKL SunOpta Inc. | AGrant or award Common Shares | +1,360 | $7.38 | $10k | 204,110 | Jan 27, 2025 |
| Oct 18, 2024 | STKL SunOpta Inc. | AGrant or award Common Shares | +1,629 | $6.02 | $9,807 | 202,750 | Oct 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.